About IC-MedTech

IC-MedTech is developing safer, more affordable treatments for infectious diseases and cancer.  

This website provides links to peer reviewed papers regarding our research and the scientific rationale behind it. In these publications we explain the concept of targeted redox, together with some of the many indications it can potentially help treat.
IC-MedTech (ICM) is a privately funded, grass roots initiative. We’ve created productive collaborations aimed at understanding and developing orally available drugs that target cellular redox. To that end ICM provides research funding for hospitals, academia, and commercial entities in the Americas, Europe and Asia interested in this innovative approach to treatment.

Targeting cellular redox is sound science, but it is still emerging and not yet considered mainstream. We know of no approved drugs that selectively target redox in diseased cells. Accordingly, ICM is developing small molecule fixed combination drugs that engage facile reduction of oxygen selectively within transformed cells. Our drug discovery platform is based on repurposed drugs, but it has also produced promising new chemical entities under investigation for indications in oncology, infectious and inflammatory diseases.  

Our mission is to translate decades of research into compelling clinical outcomes. Our vision is to help create safer, better, more affordable treatments.

Welcome to our site.